Zocdoc Stock Price, Valuation & IPO
Private company — Zocdoc is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$6.92 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 17 November 2026
Last round valuation: $2.6B
Source: D-2, February 2021, post-money
Total raised: $378M
Data last updated: 17 November 2026
About Zocdoc
Zocdoc was founded in 2007 in New York by Cyrus Massoumi, Oliver Harraz, and Nick Ganjoo; Harraz is a doctor by training, worked for seven years at McKinsey with hospitals, and has been leading the company since 2015. In the US, patients wait for a doctor's appointment for over a month on average, although 20–30% of slots in schedules remain empty. The service connects to clinic schedules and verifies the patient's insurance against the doctor's contracts, so the patient only sees those they can visit under their policy, and usually gets an appointment within one to three days. Doctors list for free and pay a one-time fee for each new patient. The network has 200 thousand verified doctors and over 10,000 insurance plans, with over 20 million patients having booked appointments. The company has been profitable since 2023, the network grew by 50% per year for three years, and revenue by 30%. Since 2026, booking has been integrated into Gemini, Amazon Health AI, and Yelp. A total of $378 million has been raised.
- Sector: Health & Pharma
Key highlights
- Blue Shield of California: seven times more records. The insurer launched a pilot in 2025. The number of hours available for booking 90 days in advance doubled to 2 million, and participants wait for an appointment on average 6 days with a 2% no-show rate.
- Yelp: Booking directly from search. Since April 2026, a Zocdoc booking button has been available on doctors' pages on Yelp. The same scenario works in the Yelp Assistant chatbot, and the patient only sees doctors covered by their insurance.
- Gemini: Zocdoc became the first booking partner. In August 2026, the service became Gemini's first partner in this category: the user searches for a doctor and confirms the appointment without leaving the chat.
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 11 February 2021 | D-2 | $29.29 | $2.6B |
Frequently asked questions
How can I buy Zocdoc stock before the IPO?
Not on a public exchange — Zocdoc is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
What is the Zocdoc stock price?
A private company has no single official share price. AXEVIL's consensus estimate is $6.92 per share as of 17 November 2026. Its most recent round implied a post-money valuation of $2.6B (February 2021).
What is Zocdoc's valuation (net worth)?
Zocdoc's most recent funding round valued the company at $2.6B post-money (February 2021) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
When will Zocdoc IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Zocdoc publicly traded?
No. Zocdoc is a private company and its shares are not listed on any public exchange.
Does Zocdoc have a stock symbol?
No. Zocdoc has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Similar companies
- Noom — Health & Pharma
- Spring Health — Health & Pharma
- Orca Bio — Health & Pharma
- Pipe — Fintech
- Exabeam — Cybersecurity
- Acorns — Fin Tech
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.